ADC Therapeutics SA (NYSE:ADCT) experienced a significant decline in its stock price on Friday, continuing a trend that began with a staggering 49.68% drop during Thursday's trading session. This downturn is attributed to serious safety concerns identified in the Phase 3 LOTIS-5 confirmatory trial, which assessed the efficacy of ZYNLONTA combined with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Although the trial met its primary endpoint with a median progression-free survival of 6.1 months, the occurrence of serious adverse events, including fatal outcomes, raised alarms among investors. In response to these findings, RBC Capital downgraded ADC Therapeutics from an Outperform to a Sector Perform rating, slashing its price target to $2. The stock is now trading at a new 52-week low of $1.13, and its performance over the past year has seen a 67.15% decline, raising concerns about its long-term viability in the market.